1359966-03-2

Basic information

• Product Name: trans-N,N-dibenzyl-4-(2-(tetrahydro-2H-pyran-2-yloxy)ethoxy)cyclohexanamine
• Synonyms: trans-N,N-dibenzyl-4-(2-(tetrahydro-2H-pyran-2-yloxy)ethoxy)cyclohexanamine
• CAS NO: 1359966-03-2
• Molecular Weight: 423.596
• Mol File: 1359966-03-2.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: trans-N,N-dibenzyl-4-(2-(tetrahydro-2H-pyran-2-yloxy)ethoxy)cyclohexanamine(CAS DataBase Reference)
• NIST Chemistry Reference: trans-N,N-dibenzyl-4-(2-(tetrahydro-2H-pyran-2-yloxy)ethoxy)cyclohexanamine(1359966-03-2)
• EPA Substance Registry System: trans-N,N-dibenzyl-4-(2-(tetrahydro-2H-pyran-2-yloxy)ethoxy)cyclohexanamine(1359966-03-2)

Safety Data

• Hazardous Substances Data: 1359966-03-2(Hazardous Substances Data)

Upstream product

• 17739-45-6 2-(2-bromoethoxy)tetrahydropyran 
• 149506-81-0 trans-4-(dibenzylamino)cyclohexanol 
• 27489-62-9 trans-4-hydroxycyclohexylamine 
• 100-39-0 benzyl bromide 
• 32503-27-8 tetra(n-butyl)ammonium hydrogensulfate 

Downstream Products

• 1359966-60-1 trans-4-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethoxy)cyclohexan-1-amine 

Relevant articles and documents

CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH

Provided herein are piperidine dione compounds having the following structure: wherein R1, R2, R3, R4, L, V, X, A, A′, a and m are as defined herein, compositions comprising an effective amount of a piperidine dione compound, and methods for treating or preventing an androgen receptor mediated disease.

CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH

Provided herein are piperidine dione compounds having the following structure: wherein R1, R2, R3, R4, L, V, X, a and m are as defined herein, compositions comprising an effective amount of a piperidine dione compound, and methods for treating or preventing an androgen receptor mediated disease.

PYRROLONE OR PYRROLIDINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS

The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are melanin concentrating hormone receptor-1 (MCHR1) antagonists which may be used as medicaments.